Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in December 2008 on request of the sponsor.
On 18 October 2000, orphan designation (EU/3/00/004) was granted by the European Commission to Ethypharm S.A., France, for fluorouracil for the treatment of glioblastoma.
Treatment of glioblastoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Ethypharm S. A.
194 Bureaux de la Colline, Batiment D
92213 Saint Cloud Cedex
Telephone: +33 1 41 12 17 20
Telefax: +33 1 41 12 17 30
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: